News Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.52 ^USD	0.00%		0.00%	-30.99%

Apr. 15	Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'	MT
Apr. 10	Zevra Therapeutics, Inc. Refinances Existing Debt with up to $100 million in Committed Capital under New Credit Facility	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	Apr. 20	PR
Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'	Apr. 15	MT
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting	Apr. 15	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	Apr. 12	PR
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility	Apr. 10	AQ
Zevra Therapeutics, Inc. Refinances Existing Debt with up to $100 million in Committed Capital under New Credit Facility	Apr. 10	CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	Apr. 04	PR
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Posts Q4 Revenue $13.2M, vs. Street Est of $11.7M	Mar. 28	MT
Zevra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	Mar. 28	AQ
Transcript : Zevra Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Zevra Therapeutics Says Phase 2 Trial of Idiopathic Hypersomnia Treatment Fulfilled Objectives	Mar. 27	MT
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia	Mar. 26	AQ
Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia	Mar. 26	CI
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Mar. 25	AQ
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024	Mar. 18	AQ
William Blair Starts Zevra Therapeutics With Outperform Rating	Mar. 12	MT
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
Sector Update: Health Care Stocks Mixed Late Afternoon	Mar. 04	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Summary

Filters